ProQR Therapeutics price target raised to $12 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on ProQR Therapeutics (PRQR) to $12 from $10 and keeps a Buy rating on the shares. The firm says that as clinical trial results on RNA editing accumulate and positive outcomes emerge in the next few months, ProQR with its Axiomer technology, “finds itself in a unique position to exploit the EON based therapeutic editing for targeting genetically validated diseases with huge unmet need.” The analyst is bullish on the data readout for AX-0810 in primary sclerosing cholangitis, which is entering the Phase 1 study with the topline data expected in Q4.